Pangenomic Study During Alcoholic Cirrhosis (CDCHC)
The recruitment status of this study is unknown because the information has not been verified recently.
Verified April 2010 by Nantes University Hospital.
Recruitment status was Recruiting
Recruitment status was Recruiting
Sponsor:
Nantes University Hospital
Information provided by:
Nantes University Hospital
ClinicalTrials.gov Identifier:
NCT01065233
First received: February 8, 2010
Last updated: August 12, 2011
Last verified: April 2010
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Hepatocellular carcinoma (HCC) is a frequent complication of cirrhosis. Occurrence of HCC could be linked with multiple functional region of genome.
The determining of a genomic mapping of " single nucleotide polymorphisms " (SNPs) permit to perform some genetic link studies with pathologies without clear hereditary disposition.
In this study, the investigators will identify predictives genetic polymorphism of HCC.
| Condition | Intervention |
|---|---|
|
Alcoholic Cirrhosis |
Genetic: DNA extraction |
| Study Type: | Observational |
| Study Design: | Observational Model: Case Control Time Perspective: Prospective |
| Official Title: | Genetical Predisposition in Hepatocellular Carcinoma : Pangenomic Link Study During Alcoholic Cirrhosis |
Resource links provided by NLM:
Genetics Home Reference related topics:
North American Indian childhood cirrhosis
MedlinePlus related topics:
Cirrhosis
Drug Information available for:
Deoxyribonucleic acid
U.S. FDA Resources
Further study details as provided by Nantes University Hospital:
Primary Outcome Measures:
- Existence of HCC and Pangenomic analysis of DNA polymorphism [ Designated as safety issue: No ]Existence of HCC and determination of which genetic polymorphism are predisposing to HCC or preventing for HCC
Secondary Outcome Measures:
- cirrhosis severity (compensated or not) [ Designated as safety issue: No ]Analysis of the genetic polymorphism involved in the severity of cirrhosis
Biospecimen Retention: Samples With DNA
2 blood samples of 5ml for DNA extraction
| Estimated Enrollment: | 600 |
| Study Start Date: | May 2008 |
| Estimated Study Completion Date: | May 2012 |
| Estimated Primary Completion Date: | May 2012 (Final data collection date for primary outcome measure) |
| Groups/Cohorts | Assigned Interventions |
|---|---|
|
alcoholic cirrhosis with viral infection
patient with alcoholic cirrhosis with viral infection (300 patients)
|
Genetic: DNA extraction
DNA extraction of blood sample for DNAship analysis
|
|
alcoholic cirrhosis without viral infection
patient with alcoholic cirrhosis without viral infection
|
Genetic: DNA extraction
DNA extraction of blood sample for DNAship analysis
|
Eligibility| Ages Eligible for Study: | 35 Years to 70 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Probability Sample |
Study Population
2 groups with 2 subgroups:
- patient with HCC
- HCC with Child A
- HCC with Child B/C
- patient without HCC
- Child A without HCC
- Child B/C without HCC
Criteria
Inclusion Criteria:
- 35 to 70 years old
- Compensated cirrhosis or not
- Caucasian origin of the parents
- Patient with cirrhosis (histological proof or obvious)
Exclusion Criteria:
- HIV, HBV, HCV positive
- Known Homozygotia (C282Y+/+)
- Important hepatocytary iron overload for patient with resection
- HCC non histologically prooved
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01065233
Contacts
| Contact: Cyrille Feray, MD | 0240087529 | cyrille.feray@chu-nantes.fr |
Locations
| France | |
| Nantes UH | Recruiting |
| Nantes, France, 44000 | |
| Contact: Cyrille Feray, MD 0240087529 cyrille.feray@chu-nantes.fr | |
| Principal Investigator: Cyrille Feray, MD | |
| Jean Verdier UH | Recruiting |
| Paris, France, 75000 | |
| Contact: Jean-Claude Trichet, MD 01 48 02 62 80 jean-claude.trinchet@jvr.aphp.fr | |
| Principal Investigator: Jean-Claude Trinchet, MD | |
| Paul Brousse UH | Recruiting |
| Paris, France, 75000 | |
| Contact: Didier Samuel, MD 0145593199 Didier.samuel@pbr.aphp.fr | |
| Principal Investigator: Didier Samuel, MD | |
| Rennes UH | Recruiting |
| Rennes, France, 35000 | |
| Contact: Michel Messner, MD 02 99 28 42 97 michel.messner@chu-rennes.fr | |
Sponsors and Collaborators
Nantes University Hospital
More Information
No publications provided
| Responsible Party: | Anne Omnes, CPRC - NantesUH |
| ClinicalTrials.gov Identifier: | NCT01065233 History of Changes |
| Other Study ID Numbers: | 07/8-M |
| Study First Received: | February 8, 2010 |
| Last Updated: | August 12, 2011 |
| Health Authority: | France: French Data Protection Authority |
Additional relevant MeSH terms:
|
Liver Cirrhosis Fibrosis Liver Cirrhosis, Alcoholic Carcinoma, Hepatocellular Liver Diseases Digestive System Diseases Pathologic Processes Liver Diseases, Alcoholic Alcohol-Induced Disorders Alcohol-Related Disorders |
Substance-Related Disorders Adenocarcinoma Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Liver Neoplasms Digestive System Neoplasms Neoplasms by Site |
ClinicalTrials.gov processed this record on May 19, 2013